Name: UMIN ID:
Unique ID issued by UMIN | UMIN000034371 |
---|---|
Receipt number | R000038160 |
Scientific Title | Safety assessment of repeated alternate infusion of cisplatin and gelatin fragments for balloon-occluded trans-catheter arterial chemo-embolization for treatment of hepatocellular carcinomas. |
Date of disclosure of the study information | 2018/10/29 |
Last modified on | 2022/10/05 13:37:51 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2018/10/03 21:58:35 | ||
2 | Update | 2018/10/08 15:48:06 | Last name of lead principal investigator Last name of lead principal investigator Organization Organization Division name Division name Address Address TEL Co-sponsor Co-sponsor |
|
3 | Update | 2018/10/29 19:39:53 | Date of disclosure of the study information |
|
4 | Update | 2018/11/23 21:14:17 | Key exclusion criteria Key exclusion criteria |
|
5 | Update | 2018/11/23 21:15:36 | Recruitment status |
|
6 | Update | 2019/04/04 11:14:41 | Date of IRB Anticipated trial start date Last follow-up date |
|
7 | Update | 2019/04/04 11:21:01 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
8 | Update | 2019/10/03 12:20:59 | Co-sponsor Co-sponsor |
|
9 | Update | 2020/10/03 17:15:51 | Recruitment status |
|
10 | Update | 2020/10/04 09:13:40 | Publication of results Number of participants that the trial has enrolled |
|
11 | Update | 2022/10/05 13:37:08 | URL releasing protocol URL related to results and publications Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
12 | Update | 2022/10/05 13:37:33 | Recruitment status |
|
13 | Update | 2022/10/05 13:37:52 | Publication of results |